Stay updated on Perseus Study: Daratumumab vs Standard in Untreated Myeloma Clinical Trial
Sign up to get notified when there's something new on the Perseus Study: Daratumumab vs Standard in Untreated Myeloma Clinical Trial page.
Latest updates to the Perseus Study: Daratumumab vs Standard in Untreated Myeloma Clinical Trial page
- Check2 days agoChange DetectedThe website has been updated from version 2.14.1 to 2.14.2.SummaryDifference0.0%
- Check9 days agoNo Change Detected
- Check17 days agoChange DetectedThe website has been updated from version 2.14.0 to 2.14.1.SummaryDifference0.0%
- Check24 days agoChange DetectedThe website has updated the 'type of intervention' feature from version 2.13.3 to 2.14.0, indicating a significant change in this functionality.SummaryDifference0.1%
- Check38 days agoChange DetectedThe European Myeloma Network has added new results related to Velcade, including updated definitions and metrics for progression-free survival (PFS), overall response rates (ORR), and MRD negativity rates, with a maximum follow-up time of 54.41 months, while previous entries regarding post-consolidation MRD negativity and various timelines for response assessments have been removed.SummaryDifference28%
- Check53 days agoChange DetectedThe website has been updated from version 2.13.2 to 2.13.3.SummaryDifference0.0%
- Check60 days agoChange DetectedThe website has updated the contact details section for the study, clarifying that it now provides information for individuals who can answer questions about joining the study and includes a reference to the Contacts and Locations section.SummaryDifference1%
Stay in the know with updates to Perseus Study: Daratumumab vs Standard in Untreated Myeloma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Perseus Study: Daratumumab vs Standard in Untreated Myeloma Clinical Trial page.